Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use YUVIWEL safely and effectively. See full prescribing information for YUVIWEL. YUVIWEL® (navepegritide) for injection, for subcutaneous use Initial U.S. Approval: 2026
Medication labelWhy this: Advisory · dailymed-prescription
YUVIWEL® is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
- generic_name
- navepegritide
- brand_name
- Water
- product_names
- Navepegritide, Water
- ndc
- 73362-201, 73362-201-02, 73362-201-01, 73362-205, 73362-205-01, 73362-801, 73362-801-01, 73362-202, 73362-202-02, 73362-202-01, 73362-206, 73362-206-01, 73362-203, 73362-203-02, 73362-203-01, 73362-207, 73362-207-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en